| 货号 | MAB292-500 |
| 别名 | C11orf43; chromosome 11 open reading frame 43; FLJ22066; FLJ44734; IGF2; IGF-2; IGF-II; insulin-like growth factor 2 (somatomedin A); insulin-like growth factor II; insulin-like growth factor type 2; MSA; PP9974; somatomedin-A | 全称 | Insulin-like Growth Factor II |
| 反应种属 | Human |
| 应用 | Neutralization |
| 目标/特异性 | Detects human IGF-II in direct ELISA and Western blots. This antibody shows 100% cross-reactivity with recombinant mouse (rm) IGF‑II and no cross-reactivity with recombinant human IGF-I or rmIGF-I. |
| 使用方法 | Neutralization: Measured by its ability to neutralize IGF‑II-induced proliferation in the MCF‑7 human breast cancer cell line. Karey, K.P. et al. (1988) Cancer Research 48:4083. The Neutralization Dose (ND50) is typically 2-12 µg/mL in the presence of 14 ng/mL Recombinant Human IGF‑II. |
| 来源 | Monoclonal Mouse IgG1 Clone # 75015 |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 3481 (Human); 16002 (Mouse) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells. | |
| 纯化方式 | Protein A or G purified from ascites |
| 免疫原 | E. coli-derived recombinant human IGF-II Ala25-Glu91 Accession # P01344.1 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.5 mg/mL in sterile PBS. |
| 背景 | Insulin-like growth factor I (also known as somatomedin C and somatomedin A) and insulin-like growth factor II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved (100% identity between human, bovine, and porcine proteins) and exhibit cross-species activity. IGF-II is a potent mitogenic growth factor. However, unlike IGF-I which has important postnatal roles, the growth-promoting function of IGF-II is limited to embryonic development. Two specific cell surface receptors that bind IGF-I and IGF-II have been identified. The type I IGF receptor that participates in IGF signaling is structurally related to the insulin receptor. It is a disulfide-linked heterotetrameric transmembrane glycoprotein with an intracellular tyrosine kinase domain. Type I IGF receptor binds IGF-I with higher affinity than IGF-II. The type II IGF receptor which binds IGF-II with much higher affinity than IGF-I is also the cation-independent mannose 6-phosphate receptor. At the present time, it is not known if the type II IGF receptor participates in the IGF signaling pathway. An additional unknown receptor which mediates IGF‑II signaling has also been proposed. Circulating IGFs exist in complexes bound to IGF binding proteins. Currently, at least six high affinity binding proteins have been identified. |
| 运输条件 | Blue Ice |
| 存放说明 | -20℃ |
| 参考文献 |
|
Cell Proliferation Induced by IGF‑II and Neutralization by Human IGF-II Antibody. Recombinant Human IGF‑II (Catalog # 292-G2) stimulates proliferation in the MCF‑7 human breast cancer cell line in a dose-dependent manner (orange line), as measured by Resazurin (Catalog # AR002). Proliferation elicited by Recombinant Human IGF‑II (14 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IGF-II Monoclonal Antibody (Catalog # MAB292). The ND50 is typically 2-12 µg/mL. |
